A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Blood
Authors: Guillermo Garcia-Manero, Xuelin Huang, Monica Cabrero, Courtney D. DiNardo, Naveen Pemmaraju, Naval G. Daver, Gautam Borthakur, William G Wierda, Tapan Kadia, Yesid Alvarado, Jorge E. Cortes, Nitin Jain, Farhad Ravandi, Elias Jabbour, Mark Brandt, Troy Sneed, Victoria Sukholutsky, Sherry Pierce, Zachary Bohannan, Hagop M. Kantarjian
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2291877792